gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · FEMYHealthcareSurgical Instruments

Femasys Inc. Common Stock (FEMY)

$1.44+2.86%
Close Nov 4, 2026 · split-adjusted
Nov 3, 2026$1.40▼ 89.35% in range
Nov 3, 2025Low $1.32 · High $122.56Nov 3, 2026
What changed · written from our data
As of Nov 4, 2026

Femasys closed at $1.44 on Nov 4, up 2.86%, 98.8% below its 52-week closing high. Volume of 94.8K shares was 0.89× its 20-day average (close to normal).

Split-adjusted performance: -30.8% over one month, -84.1% over six months, -89.0% over one year.

In the quarter ended Jun 30, 2026, revenue was $331.83K, down 18.9% from a year earlier, with a net margin of -1346.8%.

Short interest was 164.1K shares at the Oct 15 settlement, down 71.6% from the prior report (2.4% of float, 1.5 days to cover).

Market cap$12.1M8.4M shares
Revenue · quarter$331.8K−18.9% YoY
Diluted EPS$-1.33—
P/E · TTM—P/S 5.2×
Net margin-1,346.8%Gross 57.1%
Dividend yieldNone
52-week range1.32 – 122.56−98.8% from high
Volume94.8K0.89× 20-day avg
Volatility · 60d91.2%Annualised
Short % of float2.4%1.5 days to cover
Net cash-$2.1MCash $1.4M
Next earnings—Not scheduled
Split-adjusted performance
1W +2.1%1M −30.8%3M −51.2%6M −84.1%YTD −87.5%1Y −89.0%3Y −94.8%5Y −99.0%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Surgical Instruments

Percentile among 110 companies (100 = best)

6-month momentum5
Revenue growth8
Net margin5
Value (low P/E)—
Size17

Industry medians: 6-month return −4.0%, revenue growth +8.9%, net margin −8.2%, P/E 30.5×.

Short interest

Details →
Shares short164.1K−71.6% vs prior
Days to cover1.5Settled Oct 15
% of float2.4%
Short vol. 10d36.0%of daily volume

Closest peers by size in Surgical Instruments

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
FEMYFemasys$1.44+2.86%−84.1%−18.9%−1346.8%—$12.1M
SINTSiNtx Technologies$1.66−3.49%−30.8%+199.3%−803.5%—$12.5MCompare
GUTSFractyl Health$0.9725+8.27%−89.0%———$12.9MCompare
PAVMPAVmed$1.66−8.79%−76.3%+450.0%−16603.0%—$13.3MCompare
ICUSeaStar Medical Holding$2.04+2.00%−58.1%+82.0%−606.5%—$10.8MCompare
CTSOCytosorbents$4.56+0.44%−60.0%+0.2%−45.9%—$14.4MCompare
MODDModular Medical$1.67−5.65%−57.3%———$15.9MCompare
NMTCNeuroOne Medical Technologies$0.9500−3.06%−77.9%+16.3%−101.7%—$8.7MCompare
PMIPicard Medical$7.19−7.58%−38.0%—−191.6%—$16.8MCompare

News about Femasys

All news →
Femasys Partners with SandsRx Pharmacy to Support FemaSeed® Fertility Portfolio Launch to OB/GYNsGlobeNewswire Inc. · Oct 20, 2026▲ PositiveFemasys Doubles Enrolling Sites in FemBloc FINALE Pivotal Trial for Non-Surgical Permanent Birth ControlGlobeNewswire Inc. · Oct 14, 2026▲ PositiveFemasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG™ CatheterGlobeNewswire Inc. · May 13, 2026▲ Positive

Quick answers

What does Femasys do?
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics.
What is FEMY's market cap?
$12.06M, based on the Nov 4 close of $1.44.
Does Femasys pay a dividend?
No regular cash dividend has been paid in the last year.
How much of FEMY is sold short?
164.1K shares, 2.4% of float, as of Oct 15, 2026.
What sector is FEMY in?
Healthcare, in the Surgical Instruments industry.

About Femasys

Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.

HQ: Suwanee, GA54 employeesListed Jun 18, 2021femasys.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology